Emergent BioSolutions Wins 2013 North American Maintenance Excellence Award

Emergent BioSolutions (NYSE:EBS) today announced that its facility in Lansing, Michigan has been recognized with the 2013 North American Maintenance Excellence (NAME) Award by the Foundation for Industrial Maintenance Excellence. The NAME Award, considered the most prestigious recognition within the industrial maintenance discipline, honors North American organizations that excel in performing maintenance processes that enable operational excellence.

“Emergent is honored to be recognized as an industry leader in maintenance processes and strategies,” said Adam Havey, Emergent’s executive vice president and biodefense division president. “At Emergent we are dedicated to innovation and we understand the important role process improvement plays in our overall company mission.”

Emergent was selected based on the company’s pursuit, dedication, and demonstration of operational and maintenance excellence. During a four-day, on-site audit, the NAME audit team evaluated the company on 14 characteristics grouped into three major themes: organization, work processes, and materials management. Emergent’s key strengths include: Maintenance and Calibration systems; qualification of equipment; Reliability Engineering; Lean 5S program; and people development, among others.

The objectives of the NAME program are to:

  • Increase the awareness of maintenance as a competitive edge in safety, cost, quality, service and equipment performance,
  • Identify industry leaders, along with potential or future leaders, and highlight "best" practices in maintenance management,
  • Share successful maintenance strategies and the benefits derived from implementation, and
  • Understand the need for managing change and stages of development to achieve maintenance excellence.

About Emergent BioSolutions

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information may be found at www.emergentbiosolutions.com. Follow us on twitter: @emergentbiosolu.

Contacts:

Emergent BioSolutions
Investors Contact:
Robert G. Burrows, Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt, Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.